Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brave Ace study
jRCTs031220058Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, ramucirumab, aflibercept, irinotecan, fluorouracil and 1 more in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Jun 2022; status: active, not recruiting.
02
Drugs
bevacizumabramucirumabafliberceptirinotecanfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCTs031220058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220058.